Ozempic Eased Daily Burdens of Diabetes and Kidney Disease in New Trial

Staff
By Staff
7 Min Read
For people with kidney disease and type 2 diabetes, newer GLP-1 drugs like Ozempic (semaglutide) have produced some remarkable results, from slowing disease progression to reducing the risk of early death.
Findings presented this week at the European Renal Congress in Glasgow suggest that semaglutide can boost quality of life as well: In a new trial, adults taking this GLP-1 reported the equivalent of around 8 more days of full health per year than similar adults taking a placebo. The full results have not yet been published in a peer-reviewed journal.

“We were surprised by the extent of the quality-of-life benefits seen with semaglutide, because they were not only clinically meaningful, but consistently experienced across multiple aspects of daily life, including physical functioning and overall well-being,” says the lead study author, Johannes Mann, MD, a professor of medicine at the University of Erlangen-Nürnberg and the department director of nephrology, hypertension, and rheumatology at Munich General Hospitals in Germany.

More Healthy Days on Semaglutide

For the new study, researchers randomly assigned more than 3,500 adults with both chronic kidney disease and type 2 diabetes to receive either once-weekly semaglutide or a placebo (sham drug).

Read the full article here

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *